title: Effect of university of wisconsin and histidine-tryptophan-ketoglutarate preservation solutions on blood potassium levels of patients undergoing living-donor liver transplantation.
abstract: BACKGROUND
  The potassium content of University of Wisconsin solution (UW) is 125 mEq/L and that of histidine-tryptophan-ketoglutarate solution (HTK) only 9 mEq/L. The aim of the present study was to analyze their effects to change potassium levels on reperfusion among patients undergoing living-donor liver transplantation.
  
  
  METHODS
  Anesthesia records of adult living-donor liver transplant patients were reviewed retrospectively. Patients received liver graft preserved in UW were grouped in group I (GI) and HTK in group II (GII). The potassium levels in the anheptic phase were compared with those 5 minutes after reperfusion using paired Student t tests. P values of <.05 were regarded to be significant.
  
  
  RESULTS
  Eighty-five GI patients showed the potassium significantly decreased from 3.76±0.70 to 3.60±0.74, whereas the change among 355 GII patients was almost unremarkable: 4.00±0.57 to 3.96±0.06 mEq/L.
  
  
  CONCLUSIONS
  Although UW contains a higher potassium content, it seems to have no negative impact on changes in serum potassium levels; in contrast it decreased the potassium level significantly at 5 minutes after reperfusion. Both preservation solutions maintain the patients' potassium levels within the normal range.
authors.affiliation: Department of Anesthesiology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan.
authors.forename: S-E
authors.initials: SE
authors.lastname: Juang
authors.forename: H-W
authors.initials: HW
authors.lastname: Huang
authors.forename: C-W
authors.initials: CW
authors.lastname: Kao
authors.forename: C-L
authors.initials: CL
authors.lastname: Chen
authors.forename: H-F
authors.initials: HF
authors.lastname: Lu
authors.forename: K-W
authors.initials: KW
authors.lastname: Cheng
authors.forename: C J
authors.initials: CJ
authors.lastname: Huang
authors.forename: S-C
authors.initials: SC
authors.lastname: Wu
authors.forename: B
authors.initials: B
authors.lastname: Jawan
authors.forename: C-H
authors.initials: CH
authors.lastname: Wang
mesh_terms: D000241:Adenosine / Q000009:adverse effects / Q000627:therapeutic use; D000328:Adult; D000493:Allopurinol / Q000009:adverse effects / Q000627:therapeutic use; D015415:Biomarkers / Q000097:blood; D005947:Glucose / Q000009:adverse effects / Q000627:therapeutic use; D005978:Glutathione / Q000009:adverse effects / Q000627:therapeutic use; D006498:Hepatectomy / Q000009:adverse effects; D006801:Humans; D006947:Hyperkalemia / Q000097:blood / Q000209:etiology; D007328:Insulin / Q000009:adverse effects / Q000627:therapeutic use; D016031:Liver Transplantation / Q000009:adverse effects; D019520:Living Donors; D008353:Mannitol / Q000009:adverse effects / Q000627:therapeutic use; D008875:Middle Aged; D009926:Organ Preservation / Q000009:adverse effects / Q000379:methods*; D019188:Organ Preservation Solutions / Q000009:adverse effects / Q000627:therapeutic use*; D011188:Potassium / Q000097:blood*; D011189:Potassium Chloride / Q000009:adverse effects / Q000627:therapeutic use; D011343:Procaine / Q000009:adverse effects / Q000627:therapeutic use; D011887:Raffinose / Q000009:adverse effects / Q000627:therapeutic use; D012016:Reference Values; D015424:Reperfusion; D012189:Retrospective Studies; D012307:Risk Factors; D013624:Taiwan; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D015415:Biomarkers; C039984:Bretschneider cardioplegic solution; D007328:Insulin; D019188:Organ Preservation Solutions; C055206:University of Wisconsin-lactobionate solution; D008353:Mannitol; D011343:Procaine; D000493:Allopurinol; D011189:Potassium Chloride; D005978:Glutathione; D005947:Glucose; D000241:Adenosine; D011887:Raffinose; D011188:Potassium